Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies

Table 1 Current clinical trials for pancreatic cancer

Target molecule	ClinicalTrials.gov identifier	Sponsor	Agent	Treatmentsetting	Studyphase	Comments
EGFR	NCT00561990	Oncoscience AG	Nimotuzumab	First line	II/III	GEM ± nimotuzumab
	NCT02395016	Biotech Pharmaceutical	Nimotuzumab	First line	III	GEM ± nimotuzumab
MEK	NCT01222689	National Cancer Institute	selumetinib	First line	II	Selumetinib + erlotinib
PI3K	NCT01571024	UNC Lineberger Comprehensive Cancer Center	BKM120	First line	I	BKM120 + mFOLFOX6
Akt	NCT01028495	Rexahn Pharmaceuticals	RX-0201	First line	II	RX0201 + GEM
mTOR	NCT00981162	Roswell Park Cancer Institute	Everolimus	Second line	I/II	Everolimus + sorefenib
Angiogenesis	NCT01509911	Tiltan Pharma Ltd	TL-118	First line	II	TL-118 + GEM
Src	FOLFOX-D, NCT01652976	University of Florida	Dasatinib	First line	II	5-Fluorouracil + leucovorin + oxaliplatin + dasatinib
Jak	NCT01423604	Incyte Corporation	Ruxolitinib	Second line	II	Ruxolitinib + capecitabine
	NCT01822756	Incyte Corporation	Ruxolitinib	First line	I	Ruxolitinib + gemcitabine or nab-paclitaxel
Notch	NCT01098344	Cancer Research UK	MK0752	First line	I	MK0752 + GEM
Hedgehog	NCT01130142	Infinity Pharmaceuticals, Inc.	IPI-926	First line	I/II	IPI-926 + GEM
Wnt	NCT01351103	Novartis Pharmaceutical	LGK974	First line	I	LGK974 alone
	NCT01302405	Prism Pharma Co., Ltd.	PRI-724	First line	I	PRI-724 alone
	NCT02050178	OncoMed Pharmaceuticals, Inc	OMP-54 F28	First line	I	GEM + nab-paclitaxel + OMP-54 F28
	NCT02005315	OncoMed Pharmaceuticals, Inc	Vantictumab(OMP-18R5)	First line	I	GEM + nab-paclitaxel + vantictumab
Stroma	Halo-109-202, NCT01839487	Halozyme Therapeutics	PEGPH20(hyaluronidase)	First line	II	GEM + nab-paclitaxel ± PEGPH20
	S1313, NCT01959139	Southwest Oncology Group	PEGPH20	First line	I/II	FOLFIRINOX ± PEGPH20
PARP	NCT01585805	National Cancer Institute	Veriparib	First line	II	GEM + cisplatin ± veriparib
	NCT01296763	Sidney Kimmel Comprehensive Cancer Center	Olaparib	First line	I/II	Irinotecan + cisplatin + mitomycin C ± olaparib
Others	NCT01210911	Academisch Medisch Centrum	Metformin	First line	II	Erlotinib + metformin + GEM
	NCT01373164	Eli Lilly and Company	LY2157299(TGF-b inhibitor)	First line	II	LY2157299 + GEM
	NCT01621243	Momenta Pharmaceuticals, Inc	M402 (heparan sulfate)	First line	I/II	GEM + nab-paclitaxel ±M402
	NCT01783171	National Cancer Institute (NCI)	Dinaciclib	First line	I	Dinaciclib + MK-226

GEM: Gemcitabine.